LEUVEN, Belgium, April 14, 2014 (GLOBE NEWSWIRE) -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, notes the recent media speculation regarding its strategic review.
As announced on 24 February 2014, ThromboGenics is currently exploring strategic options for the Company, to allow it to realize the significant commercial potential of JETREA® in the US, and to fully exploit the Company's proven product development capabilities.
The strategic review is at a preliminary stage. The Company does not intend to comment further on market speculation unless and until it otherwise deems further disclosure is appropriate or required.Ends
|ThromboGenics Wouter Piepers, Global Head of Corporate Communications/ IR +32 16 75 13 10 / +32 478 33 56 32 email@example.com||Citigate Dewe Rogerson David Dible Tel: +44 20 7638 9571 firstname.lastname@example.org|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV